debt_leverage_profile
0.00x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low direct sensitivity; VYNE carries minimal long-term debt post-pipeline restructuring, so 200bps rate rise has negligible interest expense impact
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Active pharmaceutical ingredient sourcing from India/China CMOs; regulatory approval bottlenecks at FDA represent primary chokepoints
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue; company is US-focused specialty pharma, sovereign currency devaluation exposure is near-zero
Inferred
Agent_Inference
geographic_footprint
Substantially all revenue is US-based; no material exposure to foreign currency devaluation in top international markets
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single contract manufacturing organizations (CMOs) for foam-based topical formulations represent non-substitutable input risk exceeding 30% of COGS
Inferred
Agent_Inference
business_model_type_primary
Cloud termination would disrupt internal operations and CRM but not core product delivery; impact moderate, 60-90 day recovery feasible
Inferred
Agent_Inference
business_model_type_secondary
Specialty pharmaceutical prescription drug sales; cloud dependency is administrative, not product-delivery critical
Inferred
Agent_Inference
switching_cost_profile
Minimal API coupling risk; company operates traditional pharma commercial model without significant third-party API dependencies
Inferred
Agent_Inference
howey_test_risk_index
Prescription drug revenue model fails Howey Test; no investment contract, profit expectation, or common enterprise element present
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR exposure given negligible EU operations; CCPA exposure moderate via patient data and HCP targeting databases
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; VYNE holds no dominant market position, faces generic and branded competition in dermatology segment
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional prescription-fill revenue; no meaningful recurring subscription component, ~95% transactional
Inferred
Agent_Inference
monetization_vector
Per-prescription net revenue after gross-to-net deductions (rebates, chargebacks); highly transactional specialty pharma model
Inferred
Agent_Inference
pricing_architecture
WAC-based pricing with significant gross-to-net erosion (30-50%); vulnerable to PBM rebate pressure and formulary exclusion risk
Inferred
Agent_Inference
pricing_power_rating
Low; payer leverage, generic competition, and formulary dynamics severely constrain net pricing power in topical dermatology
Inferred
Agent_Inference
target_gross_margin_bracket
Specialty pharma gross margins historically 60-75% at product level, but SG&A burden renders operating margin deeply negative
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider problem; prescription drugs require patient co-pay and physician authorization, limiting unpaid consumption
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is moderately headcount-linear; sales force expansion required to drive new prescriber adoption, sublinear at scale
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost of growth; each new territory requires additional sales reps, medical affairs staff, and marketing spend
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; VYNE operates no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, cost per new prescriber would decline via digital detailing and data targeting, but field force costs remain significant
Inferred
Agent_Inference
network_effect_present
No network effects present; prescription drug adoption is physician/patient driven without platform interdependency
Inferred
Agent_Inference
asset_efficiency_ratio
-88.6% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; dermatology conditions are chronic but elective visits decline in recessions, reducing new prescription starts
Inferred
Agent_Inference
customer_segment_primary
Dermatologists and primary care physicians writing topical antibiotic/anti-inflammatory prescriptions; fragmented prescriber base
Inferred
Agent_Inference
customer_segment_secondary
Retail and specialty pharmacies (Walgreens, CVS, Express Scripts) as distribution channel; moderate concentration among top 3 wholesalers
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.0% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001566044
High
SEC-EDGAR
ticker
VYNE
High
SEC-EDGAR